The increasingly used NarxCare narcotics score does not predict adverse outcomes or patient dissatisfaction after elective spine surgery, according to the new research by Anoop Raj Galivanche, BS, of Yale University School of Medicine and colleagues. They write, “Although there are many reasons to address preoperative patient narcotic utilization, the current study did not identify perioperative outcome/satisfaction differences based on preoperative narcotics use criteria.”
Study Questions Routine Use of Previous Narcotic Use to Predict Surgical Risks
The study included 346 patients undergoing elective spinal surgery at the authors’ hospital over a six-month period. The hospital routinely estimated each patient’s previous use of opioid pain medications with the automated NarxCare narcotic score.
The NarxCare score approximates a patient’s level of previous opioid use, calculated from state prescription drug monitoring programs (PDMPs). The score accounts not only for number and dosage of opioid prescriptions, but also for the number of prescribers, number of pharmacies, and overlapping prescriptions. NarxCare scores range from 0 (no previous opioid use) to 999 (highest level of use).
On admission to the hospital for spinal surgery, nearly 80 percent of patients had a NarxCare score of greater than zero, indicating at least one recent opioid prescription. About six percent were in the highest category of NarxCare score (500 or higher). The researchers evaluated whether the preoperative NarxCare score could predict patient outcomes after spinal surgery. About four percent of patients had some type of adverse event.
After controlling for other patient characteristics, the rate of adverse outcomes was not significantly different for patients at different levels of NarxCare score. That included both minor and serious adverse events, as well as the rates of repeat surgery or repeat hospitalization. (There were no deaths within 30 days after surgery.)
NarxCare scores were also unrelated to patient satisfaction scores – increasingly viewed as an important indicator of the quality of healthcare.
Use of prescription opioid medications has increased dramatically in recent years, and these medications are frequently prescribed for patients with back pain. There is concern that previous opioid use might affect the risk of complications and other adverse outcomes of surgery, including spinal surgery. However, previous studies of this issue have reached conflicting results. State PDMPs are viewed as an important tool for responding to the ongoing opioid epidemic.
The new study finds no differences in adverse events or patient satisfaction after spinal surgery for patients with higher preoperative NarxCare scores. “In light of the fact that federal reimbursement may be affected by [patient satisfaction] scores, these findings are particularly relevant,” Mr. Galivanche and colleagues conclude.
Recognized internationally as the leading journal in its field, Spine (www.spinejournal.com) is an international, peer-reviewed, bi-weekly periodical that considers for publication original articles in the field of spine. It is the leading subspecialty journal for the treatment of spinal disorders. Only original papers are considered for publication with the understanding that they are contributed solely to Spine. According to the latest ISI Science Citation Impact Factor, Spine is the most frequently cited spinal deformity journal among general orthopaedic journals and subspecialty titles.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2018 annual revenues of €4.3 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 18,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit http://healthclarity.wolterskluwer.com and follow us on LinkedIn and Twitter @WKHealth.